Merck & Co. MRK
SEC filings (XBRL) · quarterly · fiscal year ends December 31
Pick a second metric to compare.
Source: SEC EDGAR 10-Q/10-K XBRL, CIK 310158; every value is traced to its filing on EDGAR. Retrieved Oct 11, 2026. Quarters labelled by fiscal quarter with the calendar period end. Q4 = annual minus Q1–Q3; cash-flow quarters derived from year-to-date figures.
Last 84 quarters
| Q3 2024Sep 30, 2024 | Q4 2024Dec 31, 2024 | Q1 2025Mar 31, 2025 | Q2 2025Jun 30, 2025 | Q3 2025Sep 30, 2025 | Q4 2025Dec 31, 2025 | Q1 2026Mar 31, 2026 | Q2 2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.7B | $15.6B | $15.5B | $15.8B | $17.3B | $16.4B | $16.3B | $16.6B |
| Operating income | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | — No figure for Q2 2009–Q2 2026: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal. |
| Net income | $3.2B | $3.7B | $5.1B | $4.4B | $5.8B | $3.0B | −$4.2B | −$1.3B |
| Capital spending | $0.8B | $0.9B | $1.3B | $0.8B | $1.0B | $1.0B | $1.0B | $0.9B |
| Operating cash flow | $9.3B | $3.5B | $2.5B | $3.3B | $7.8B | $2.9B | $3.9B | $5.4B |
| Free cash flow | $8.5B | $2.5B | $1.2B | $2.5B | $6.8B | $1.8B | $2.9B | $4.5B |
| Capex / operating cash flow | 8.4% | 27.2% | 53.1% | 23.2% | 12.6% | 36.2% | 25.3% | 16.6% |
| Shares outstanding | 2.530B | 2.526B | 2.511B | 2.498B | 2.482B | 2.472B | 2.470B | 2.467B |
| Share count change, y/y | −0.2% | −0.3% | −0.9% | −1.5% | −1.9% | −2.1% | −1.6% | −1.2% |
| Diluted shares (weighted avg.) | 2.541B | — No figure for Q4 2024: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction. | 2.531B | 2.513B | 2.498B | — No figure for Q4 2025: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction. | 2.472B | 2.470B |
Operating income: Not presented by the company: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal..
— Diluted shares (weighted avg.): No figure for Q4 2024: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction.
— Diluted shares (weighted avg.): No figure for Q4 2025: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction.
Diluted shares (weighted avg.): fiscal Q4 is blank because the 10-K gives 12-month figures only.
† Amended filing: Shares outstanding, Q4 2023. Cover from 10-K/A filed 2024-04-11, which amends the original filing for the same period; original 10-K cover showed 2,532,643,872. 10-K/A on EDGAR
XBRL tags used
| Revenue | Revenues | Jun 2009 to Dec 2010 |
|---|---|---|
SalesRevenueNet | Mar 2011 to Mar 2011 | |
SalesRevenueGoodsNet | Jun 2011 to Mar 2017 | |
Revenues | Jun 2017 to Jun 2026 | |
| Operating income | Not presented by the company: No us-gaap:OperatingIncomeLoss fact in any Merck filing; the income statement goes from costs to income before taxes with no operating-income subtotal. | |
| Net income | NetIncomeLoss | Jun 2009 to Jun 2026 |
| Capital spending | PaymentsToAcquireProductiveAssets | Jun 2009 to Sep 2022 |
PaymentsToAcquirePropertyPlantAndEquipment | Dec 2022 to Jun 2026 | |
| Operating cash flow | NetCashProvidedByUsedInOperatingActivities | Jun 2009 to Mar 2021 |
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Jun 2021 to Dec 2021 | |
NetCashProvidedByUsedInOperatingActivities | Mar 2022 to Jun 2026 | |
| Free cash flow | ocf - capex: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquireProductiveAssets | Jun 2009 to Mar 2021 |
ocf - capex: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations, PaymentsToAcquireProductiveAssets | Jun 2021 to Dec 2021 | |
ocf - capex: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquireProductiveAssets | Mar 2022 to Sep 2022 | |
ocf - capex: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment | Dec 2022 to Jun 2026 | |
| Capex / operating cash flow | capex / ocf * 100: PaymentsToAcquireProductiveAssets, NetCashProvidedByUsedInOperatingActivities | Jun 2009 to Mar 2021 |
capex / ocf * 100: PaymentsToAcquireProductiveAssets, NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Jun 2021 to Dec 2021 | |
capex / ocf * 100: PaymentsToAcquireProductiveAssets, NetCashProvidedByUsedInOperatingActivities | Mar 2022 to Sep 2022 | |
capex / ocf * 100: PaymentsToAcquirePropertyPlantAndEquipment, NetCashProvidedByUsedInOperatingActivities | Dec 2022 to Jun 2026 | |
| Shares outstanding | dei:EntityCommonStockSharesOutstanding | Jun 2009 to Jun 2026 |
| Diluted shares (weighted avg.) | WeightedAverageNumberOfDilutedSharesOutstanding | Jun 2009 to Jun 2026 |
Where a company changed tags, each quarter uses the tag it was reported under; the newest tag is primary.